Bank of America
CNSP icon

Bank of America’s CNS Pharmaceuticals CNSP Stock Holding History

Bank of America’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4
Closed -$21 – 5953
2025
Q4 		$21 Hold
4
– – ﹤0.01% 7112
2025
Q3 		$36 Hold
4
– – ﹤0.01% 8080
2025
Q2 		$40 Buy
4
+3
+300% +$38 ﹤0.01% 8143
2025
Q1 		$12 Hold
1
– – ﹤0.01% 8198
2024
Q4 		$53 Buy
+1
New +$71 ﹤0.01% 7851
2024
Q3 		– Hold
0
– – – 7904
2024
Q2 		– Hold
0
– – – 8152
2024
Q1 		– Hold
0
– – – 7322
2023
Q4 		– Hold
0
– – – 7936
2023
Q3 		– Hold
0
– – – 7635
2023
Q2 		– Hold
0
– – – 7534
2023
Q1 		– Hold
0
– – – 7559
2022
Q4 		– Hold
0
– – – 7765
2022
Q3 		– Hold
0
– – – 7874
2022
Q1 		– Hold
0
– – – 8312
2021
Q4 		– Hold
0
– – – 8259
2021
Q3 		– Hold
0
– – – 7654
2021
Q2 		– Hold
0
– – – 7455
2020
Q3 		– Hold
0
– -$2K – 6919
2020
Q2 		– Hold
0
– – – 6660
2020
Q1 		– Hold
0
– – – 6893

Other funds holding CNSP

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Bank of America's CNSP Position: Q1 2026 in Review

Bank of America sold out of CNS Pharmaceuticals (CNSP) in Q1 2026, closing a stake of 4 shares — an estimated $21 sold.

Bank of America first reported a position in CNSP in Q4 2024 and held it in 5 quarters. The position peaked at $53 in Q4 2024. 12 funds tracked by Wall St. Rank hold CNSP as of Q1 2026.

  • Bank of America reported no remaining CNS Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 4 CNS Pharmaceuticals shares in Q1 2026, an estimated $21.
  • Bank of America first reported a position in CNS Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • Bank of America's CNS Pharmaceuticals position peaked at $53 in Q4 2024.
  • 12 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.